title: Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
abstract: Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD. Although carbidopa and trihydroxybenzylhydrazine (the in vivo hydrolysis product of benserazide) are both powerful irreversible DDC inhibitors, they are not selective because they irreversibly bind to free PLP and PLP-enzymes, thus inducing diverse side effects. Therefore, the main goals of this study were (a) to use virtual screening to identify potential human DDC inhibitors and (b) to evaluate the reliability of our virtual-screening (VS) protocol by experimentally testing the "in vitro" activity of selected molecules. Starting from the crystal structure of the DDC-carbidopa complex, a new VS protocol, integrating pharmacophore searches and molecular docking, was developed. Analysis of 15 selected compounds, obtained by filtering the public ZINC database, yielded two molecules that bind to the active site of human DDC and behave as competitive inhibitors with K(i) values ≥10 µM. By performing in silico similarity search on the latter compounds followed by a substructure search using the core of the most active compound we identified several competitive inhibitors of human DDC with K(i) values in the low micromolar range, unable to bind free PLP, and predicted to not cross the blood-brain barrier. The most potent inhibitor with a K(i) value of 500 nM represents a new lead compound, targeting human DDC, that may be the basis for lead optimization in the development of new DDC inhibitors. To our knowledge, a similar approach has not been reported yet in the field of DDC inhibitors discovery.
authors.affiliation: Department of Biochemical Sciences A Rossi Fanelli, University of Rome La Sapienza, Rome, Italy.
authors.forename: Frederick
authors.initials: F
authors.lastname: Daidone
authors.forename: Riccardo
authors.initials: R
authors.lastname: Montioli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Paiardini
authors.forename: Barbara
authors.initials: B
authors.lastname: Cellini
authors.forename: Antonio
authors.initials: A
authors.lastname: Macchiarulo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Giardina
authors.forename: Francesco
authors.initials: F
authors.lastname: Bossa
authors.forename: Carla
authors.initials: C
authors.lastname: Borri Voltattorni
mesh_terms: D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D020134:Catalytic Domain; D002626:Chemistry, Pharmaceutical / Q000379:methods; D016208:Databases, Factual; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D006801:Humans; D066298:In Vitro Techniques; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008956:Models, Chemical; D008958:Models, Molecular; D008968:Molecular Conformation; D010300:Parkinson Disease / Q000188:drug therapy*; D011485:Protein Binding; D012701:Serotonin / Q000378:metabolism; D013552:Swine
chemical_list: D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D012701:Serotonin; D004298:Dopamine